Quetiapine Multiple Dose Study [Design Issues]

posted by raghavendra_s – 2010-07-27 15:30 (5809 d 07:54 ago) – Posting: # 5685
Views: 4,164

Dear Madam/Sir,
  1. Quetiapine 200 mg XL multiple dose study is not advised in healthy subjects due to safety reasons.
  2. What are the alternate approaches to conduct the study ?
  3. Anyhow if anybody wants to go ahead with healthy subjects, can the following approach is acceptable provided the subject will be withdrawn in case of any safety issue during dose titration.
Days Dose
0 (Enrollment) Nil
1 50 mg XR (Innovator)
2 100 mg XR (Innovator)
3 200 mg XR (T or R )
4 200 mg XR (T or R )
5 200 mg XR (T or R )
6 200 mg XR (T or R ), profiling
7 Discharge
Washout 7 days (Dosing to dosing)
12 Enrollment 2
13 50 mg XR (Innovator)
14 100 mg XR (Innovator)
15 200 mg XR (R or T)
16 200 mg XR (R or T)
17 200 mg XR (R or T)
18 200 mg XR (R or T) profiling
19 Discharge

Thanks in advance.

Kind regards,

Complete thread:

UA Flag
Activity
 Admin contact
23,655 posts in 4,993 threads, 1,571 registered users;
128 visitors (0 registered, 128 guests [including 23 identified bots]).
Forum time: 23:25 CEST (Europe/Vienna)

Scientists cannot simply hang their subjectivities
up on a hook outside the laboratory door.    Ruth Bleier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5